On Tuesday, 28 January 2025, a webinar focusing on the transformative role of artificial intelligence (AI) in drug discovery will be hosted at 10am GMT / 11am CET. The event will feature prominent speakers in the field, including Dr Marissa Powers, a Solutions Architect in High Performance Computing (HPC) Life Sciences at Amazon Web Services (AWS), and Dr David Ruau, the EMEA Business Development Lead for Healthcare and Life Sciences at NVIDIA.
The webinar aims to provide insights into how generative AI and high-performance computing are changing the landscape of drug discovery. The process traditionally entails years of research and high costs, often reaching billions of dollars before a new drug can be approved for clinical use. Emerging technologies in AI, particularly generative and predictive AI, are poised to significantly reduce both the time and financial burden associated with developing new therapeutic compounds.
Attendees of the webinar will explore several key topics, including strategies to tackle common issues related to data quality and the management of multi-modal data, as well as resolving constraints associated with limited computational resources. Additionally, the speakers will elucidate how generative AI is currently impacting the drug discovery process and how accelerated computing can facilitate the building, running, and training of generative AI workloads.
The event promises to be an informative session for professionals in healthcare and pharmaceuticals, highlighting the potential advancements that AI can bring to the field of drug discovery. Registrations for the webinar are open, offering participants the opportunity to gain valuable knowledge about the future trends in AI automation within the drug development sector, as reported by Drug Discovery World.
Source: Noah Wire Services